본문 바로가기

중등도-중증의 한국인 건선 환자에서 Ustekinumab 장기 투여에 따른 효과 및 안전성 연구

Long-Term Analysis of Ustekinumab Therapy for Moderate-to-Severe Psoriasis in Korea

문서 유형
연구출판물 · 학술지 논문
등재
KCIScopus
저널 순위
Scopus Q4KCI Q3
저널
대한피부과학회지60(3) · pp.151 · 2022
피인용
Scopus 0KCI 0
FWCI (Scopus)
0
ISSN
0494-4739

저자

  1. 김연아제1저자Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea
  2. 배경남Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
  3. 손진화Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
  4. 신기혁Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
  5. 김훈수Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
  6. 고현창Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
  7. 김문범Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
  8. 신봉석Department of Dermatology, Chosun University School of Medicine, Gwangju, Korea
  9. 김병수교신저자Biomedical Research Institute, Pusan National University Hospital, Busan, Korea

초록

Background: Ustekinumab is a humanized monoclonal antibody targeting interleukin (IL)-12 and IL-23. Although popular, data on its long-term efficacy and safety in Korean patients with psoriasis are limited. Objective: To evaluate the long-term efficacy and safety of ustekinumab in Korean patients with psoriasis. Methods: A retrospective study in patients with moderate-to-severe psoriasis who had been treated with ustekinumab for at least 5 years was conducted. The sex, age, body mass index, medical records, previous psoriasis therapy, psoriasis area and severity index (PASI) scores, and adverse events were evaluated. Results: Twenty-five patients (median age 47.00 years) had been treated with ustekinumab for 5 years. The mean duration of psoriasis was 19.12±8.45 years, and the treatment duration with ustekinumab was 285.12±8.48 weeks. The baseline PASI was 17.52±7.38. PASI75 was achieved in 84% of the patients at week 28, and 96% of the patients maintained PASI75 during the 5-year follow-up period. Furthermore, 56% of patients reached PASI90 at 28 weeks, and 48% of patients maintained PASI90 for 5 years. No unexpected adverse events other than herpes zoster, herpes simplex, or elevated liver enzymes were reported. Conclusion: Ustekinumab demonstrated long-lasting efficacy with an acceptable safety profile in Korean patients with moderate-to-severe psoriasis.

키워드

EfficacyPsoriasisSafetyUstekinumab

식별자

Scopus EID
2-s2.0-85134297538
KCI
ART002825534